Key clinical point: Long-term data shows that R-CHOP is effective and safe as first-line treatment of patients with follicular lymphoma.
Major finding: Approximately one-third of patients treated with R-CHOP-14 plus G-CSF or R-CHOP-21 had no disease progression after 10 years of follow-up.
Study details: Long-term analysis of a randomized phase 2/3 trial in 299 patients with indolent B-cell lymphomas, including follicular lymphoma.
Disclosures: The study was supported by the Ministry of Health, Labor and Welfare of Japan and by the National Cancer Center Research and Development Fund of Japan. Dr. Wantanabe has received honoraria from Bristol-Myers Squibb, Takeda, Taisho Toyama, Celgene, Nippon Shinyaku, and Novartis and funding resources from TakaraBio and United Immunity to support the Department of Immuno-Gene Therapy in Mie University. Multiple coauthors reported similar relationships.
Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31.
This Week's Must Reads
'New standard of care’ for CLL in younger patients, Shanafelt TD et al. ASH 2018, Abstract LBA-4
Mutation pegged as CLL resistance mechanism to venetoclax, Blombery P et al. ASH 2018, Abstract LBA-7
Guidelines for primary central nervous system lymphoma, Fox et al. Br J Haematol. 2018 Nov 23 doi: 10.1111/bjh.15661
FLYER evaluates number of R-CHOP cycles in DLBCL, Poeschel V et al. ASH 2018, Abstract 781
Ibrutinib-based therapy improves survival in CLL, Woyach JA et al. ASH 2018, Abstract 6
Must Reads in Indolent Lymphoma
Long-term data on R-CHOP in follicular lymphoma, Wantanabe T et al. Lancet Haematol. 2018 Nov;5(11):e520-31
Bortezomib looks promising in WM mutations, Sklavenitis-Pistofidis R et al. Blood. 2018 Oct 26. doi: 10.1182/blood-2018-07-863241
Positive results for rituximab biosimilar in comparative trial, Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53
BTK inhibitor shows phase 1 results in Waldenstrom’s macroglobulinemia, Leukemia & Lymphoma 2018
The role of PTPN22 R620W in CLL, Leukemia & Lymphoma 2018